VRCA - Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou Verrica and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, April 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Caribou Biosciences, Inc. (NASDAQ:CRBU), Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA), and Playstudios, Inc. (NASDAQ:MYPS) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.
Caribou Biosciences, Inc. (NASDAQ:CRBU)
Bragar Eagel & Squire is investigating certain officers and directors of Caribou Biosciences, Inc. following a class action complaint that was filed against Caribou on April 11, 2023.
According to the complaint, the Company's Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (i) CB-010's treatment effect was not as durable as Defendants had led investors to believe; (ii) accordingly, CB-010's clinical and commercial prospects were overstated; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.
To learn more about our investigation into Caribou go to: https://bespc.com/cases/CRBU
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA)
Bragar Eagel & Squire ...